Why carry out this study?
|
Generalized pustular psoriasis (GPP) is a rare, potentially life-threatening autoinflammatory skin disease; standard treatment guidance for this condition often follows that of plaque psoriasis, despite limited evidence on the efficacy of anti-psoriatic drugs, including biologics, in GPP. |
Spesolimab is effective in treating GPP flares, but the relapsing nature of GPP means that there is an unmet need for treatments to prevent the occurrence of GPP flares, which the Effisayil™ 2 study (NCT04399837) will assess. |
What was learned from the study?
|
Effisayil™ 2 is the first placebo-controlled study in patients with GPP that focuses on flare prevention, through maintenance treatment with subcutaneous spesolimab. |
The efficacy and safety data from Effisayil™ 2 will provide valuable information on the use of maintenance spesolimab treatment in preventing GPP flares and delivering sustained symptom management. |
Introduction
Methods
Study Design
Randomization
Patient Population
Inclusion criteria | Exclusion criteria |
---|---|
Male or female patients aged ≥ 12–75 years at screening History of GPP with ≥ 2 past GPP flares with fresh pustulation (new appearance or worsening). At screening, the confirmation of history (diagnosis) of GPP is based on the consensus diagnostic criteria defined by the ERASPEN [3] and the patients must have had previous evidence (for past GPP flares) of either fever, and/or asthenia, and/or myalgia, and/or elevated C-reactive protein, and/or leukocytosis with peripheral blood neutrophilia (above ULN) GPPGA total score of 0 or 1 at screening and randomization Patients not on concurrent GPP treatment at randomization must have had ≥ 2 flares in the previous year, ≥ 1 of which must have been associated with fever, elevated CRP or WBC count, asthenia, and/or myalgia Patients on concurrent GPP treatment within 12 weeks prior to randomization must have a history of flaring during, or after dose reduction or discontinuation of, concurrent treatment Patients on concurrent treatment with retinoids, methotrexate, and/or ciclosporin must stop this treatment on the day of randomization Signed and dated written informed consent and assent in accordance with ICH-GCP and local legislation prior to admission in the study Women of child-bearing potential must be ready and able to use highly effective methods of birth control | Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome Primary erythrodermic psoriasis vulgaris Severe, progressive, or uncontrolled hepatic disease Treatment with any defined restricted medication, any drug considered by the investigator to interfere with the safe conduct of the study, or prior exposure to spesolimab or another IL-36R inhibitor biologic. Biologic treatments must not be taken for 12 weeks, or 5 half-lives (whichever is shorter), prior to randomization. Systemic immunomodulatory treatments (e.g., corticosteroids) are not permitted 4 weeks prior to randomization Increased risk of infectious complications Acute or chronic infections at randomization Active or latent tuberculosis History of allergy/hypersensitivity to the systemically administered study medication agent Malignancy within 5 years prior to screening Currently enrolled or < 30 days since ending another investigational device or drug study Pregnant or nursing women, or women planning to become pregnant during the study Patients who have undergone major surgery within 12 weeks prior to the study or have surgery planned during the study Evidence of a current or previous disease, medical condition other than GPP or other condition/finding that would compromise the safety of the patient or compromise the quality of the data |
Treatment Administration in Response to Patients Experiencing a GPP flare
Handling of Investigator-Prescribed Other Medication for GPP
Study Objectives
Study Endpoints
Definition | ||
---|---|---|
Primary endpoint | Time to first GPP flare up to Week 48 | GPP flare defined as an increase of ≥ 2 in GPPGA total score from baseline and GPPGA pustulation subscore of ≥ 2 |
Key secondary efficacy endpoint | Occurrence of at least one GPP flare up to Week 48 | GPP flare defined as an increase of ≥ 2 in GPPGA total score from baseline and GPPGA pustulation subscore of ≥ 2 |
Secondary endpoints | Time to worsening of PSS score up to Week 48 | ≥ 4-point increase in total PSS score from baseline; intake of open-label IV spesolimab or investigator-prescribed other medication for GPP will be considered as onset of worsening |
Time to first worsening of DLQI up to Week 48 | ≥ 4-point increase in total DLQI score from baseline; intake of open-label IV spesolimab or investigator-prescribed other medication for GPP will be considered as onset of worsening | |
Sustained remission | GPPGA total score of 0 or 1 at all visits up to Week 48 without intake of open-label IV spesolimab or investigator-prescribed other medication for GPP | |
Safety endpoint | Occurrence of treatment-emergent adverse events |
Outcome | Measure for assessment |
---|---|
Skin condition | GPPGA GPPASI |
Systemic aspects of the GPP flare | Systemic components of the JDA GPP Severity Score CGI-I instrument (as per JDA severity index) TPSS (measured in patients with concurrent plaque psoriasis, if applicable) |
Patient-reported outcomes | PSS Pain VAS DLQI EQ-5D-5L health questionnaire WPAI questionnaire SF-36 PGI-S PGI-C |